Compare Heron Therapeutics Inc (HRTX) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs KLA Corp. — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while KLA Corp. trades at $201.58 (market cap $256.86B). The key difference: KLA Corp. is far larger — about 3469.2× Heron Therapeutics Inc's market cap, and KLA Corp. pays a 0.47% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and KLA Corp. for 60 Days on average.
| HRTX | KLAC | |
|---|---|---|
Market Cap | $74.04M | $256.86B |
Volume | 3,668,095 | 7,016,455 |
Sector | Health | Technology |
52-Week High | $1.49 | $301.71 |
52-Week Low | $0.27 | $98.28 |
Typical Hold Time | 35 Days | 60 Days |
Enterprise Value | $180.78M | $258.11B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
KLA Corporation (KLAC) trades at $196.72, down 0.37% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported revenue of $12.16 billion in 2025, with net income of $4.06 billion and a robust net margin of 33.41%. Recent earnings beats and a significant backlog driven by AI demand highlight operational strength, while analyst consensus remains strongly positive with a $223.88 price target.
The outlook for KLAC is favorable, supported by AI-led growth in semiconductor equipment demand and solid financials, though high valuation multiples and competitive pressures pose risks. Upside potential exists if the company continues to exceed earnings expectations and capitalize on industry tailwinds, but investors should monitor margin trends and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
